Navigation Links
Competitive Tech Achieves OTCQX Listing Compliance
Date:11/21/2013

FAIRFIELD, Conn., Nov. 21, 2013 /PRNewswire/ -- Competitive Technologies, Inc., (OTCQX: CTTC) (CTI), a pain mitigation biotechnology company, was notified yesterday, Wednesday, November 20, 2013 at 2:24 EST that it had returned to good listing compliance with the OTCQX.

On June 3, 2013, CTI was notified of its non-compliance with the rules and ongoing obligations of a publicly traded OTCQX company as so delineated in Section 3.1.r.(i) of the OTCQX Rules of U.S. Companies. On or about September 27, 2013, Management requested a three month extension to rectify the compliance shortfall due to the fact that there was a new management team in place as of September 26, 2013, which had initiated a corporate reengineering initiative that would rectify the non-compliance issue in short order. OTC Markets verbally agreed to an extension deadline of December 2, 2013.

"Being back in compliance with the OTC Markets is an enormous weight lifted off of CTI's shoulders," said CTI President & CEO Conrad Mir. "The Street has responded well to the recent changes made in the Company, which has contributed to this achievement. We believe this re-compliance may greatly contribute our fourth quarter results."

About the CompanyCompetitive Technologies Inc., (CTI) is a biotechnology company developing and commercializing innovative products and technologies. CTI is the licensed distributor of the non-invasive Calmare® pain therapy medical device, which incorporates the biophysical "Scrambler Therapy"® technology developed to treat neuropathic and cancer-derived pain by Professor Giuseppe Marineo.

Forward-Looking StatementsCertain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance.  Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.Contacts:Competitive Technologies, Inc.JV Public RelationsConrad MirJanet VasquezPresident and CEOManaging Directorcmir@competitivetech.netjvasquez@jvprny.com  973.798.8882212.645.5498Scrambler Therapy®: www.scramblertherapy.org/english.htm
Calmare®: www.calmarett.com

www.competitivetech.net

 


'/>"/>
SOURCE Competitive Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Competitive Tech Reports Third Quarter 2013 Results
2. Cambridge Semantics and Linguamatics to Host Webinar on Competitive Intelligence Using Semantic Analysis
3. A*STAR IHPC and IDA to Co-Develop Innovative Cloud-Enabled Technological Solutions for Local ICT Companies to be More Competitive
4. Cambridge Semantics to Present on Smart Data and Competitive Intelligence Informatics at 2013 Pharma CI Conference & Exposition
5. United Airlines and AltAir Fuels to Bring Commercial-Scale, Cost-Competitive Biofuels to Aviation Industry
6. PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013
7. PharmaLeaders: Innovative Mid-Cap Biotechnology Benchmark Report - Financial Benchmarking, Pipeline Assessment & Competitive Analysis of Innovative Biotechs
8. Neurovascular/Interventional Neurology Market [Aneurysm Coils, Carotid Stents, Microcatheter, Microguidewire, Liquid Embolic Agents, Cerebral Angioplasty Balloons] - Global Trends & Competitive Analysis - 2017
9. Pre-Clinical Imaging (In vivo) Market - by Systems and Reagents - Competitive Analysis & Global Forecasts to 2017
10. Neurovascular/Interventional Neurology Market: Global Trends & Competitive Analysis - 2017
11. Foot & Ankle Devices Market (2012 – 2017) By Product Type (External Fixation, Internal Fixation, Joint Replacement, Prosthesis, Bracing) - Global Trends & Competitive Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... 18, 2017 , ... Whitehouse Labs has furthered its efforts ... Inc. (AMRI), the scientific staff dedicated to Extractables / Leachables & Impurities has ... in 2017. Extractable & Leachable evaluations have become increasingly more vital to successful ...
(Date:1/18/2017)... ... ... from a new study are stating that if levels of the blood test called ... there is still remaining prostate cancer cells that are more likely to come back, spreading ... an indicator of whether a man’s prostate cancer is growing or not,” stated Dr. ...
(Date:1/18/2017)... ... January 18, 2017 , ... uBiome, ... latest paper by its Science Editor, Dr. Elisabeth Bik, in the December 2016 ... Dr. Bik joined uBiome in October 2016 from her previous position at Stanford ...
(Date:1/18/2017)... DIEGO , Jan. 18, 2017  HUYA Bioscience ... of China,s pharmaceutical innovations, announced ... of Sciences Innovation and Investment Company (referred to as ... commercializing biomedical innovations discovered by leading scientists at CAS ... world. HUYA is the first company to ...
Breaking Biology Technology:
(Date:12/15/2016)... DUBLIN , Dec 15, 2016 ... Research and Markets has announced ... to their offering. The report forecasts the global military ... 2016-2020. The report has been prepared based on an ... market landscape and its growth prospects over the coming years. The report ...
(Date:12/15/2016)... 14, 2016 "Increase in mobile transactions is ... mobile biometrics market is expected to grow from USD ... 2022, at a CAGR of 29.3% between 2016 and ... the growing demand for smart devices, government initiatives, and ... "Software component is expected to grow at a high ...
(Date:12/8/2016)... -- Singulex, Inc., the leader in Next Generation Immunodiagnostics powered ... and supply agreement with Thermo Fisher Scientific, the world ... to Thermo Scientific BRAHMS PCT (Procalcitonin), a biomarker which, ... diagnose systemic bacterial infection and sepsis and in ... assessing the risk of critically ill patients for progression ...
Breaking Biology News(10 mins):